<DOC>
	<DOCNO>NCT02134431</DOCNO>
	<brief_summary>Microbicides topical medicine prevent infection Human Immunodeficiency Virus ( HIV ) . Microbicide medicine yet study adolescent , key group become infect HIV world . From past research , know different age people experience age-related change body cause difference process medication . In study , gut tissue sample ( gut biopsy ) 12 HIV-negative volunteer collect . These piece tissue infect HIV laboratory develop model use test certain drug HIV infection . We use tissue test drug call tenofovir HIV infection . We determine whether drug decrease HIV infection gut biopsy . In study , also measure HIV level level tenofovir gut blood sample 12 people already take drug . This information determine whether level drug find gut protect HIV . The result compare age group adolescent adult . Subjects undergo common procedure call low endoscopy ( colonoscopy flexible sigmoidoscopy ) obtain gut biopsy sample . The central hypothesis tissue drug profile tenofovir ( TFV ) active component , tenofovir disoproxil fumarate ( TDF ) , tissue infectibility vary young ( 10-14 year old ) versus old adolescent ( 18-21 year old ) , differ adult ( &gt; 21 year ) . Specifically , young HIV positive adolescent low level tissue tenofovir compare old HIV positive adolescent adult age-dependent manner . Additionally , biopsy younger HIV negative adolescent : 1 ) high rate infection compare biopsy older HIV negative adolescent infect low dose virus ; 2 ) low percent suppression tissue infectivity compare biopsy older HIV negative adolescent use low dose tenofovir .</brief_summary>
	<brief_title>Relationship Tenofovir With HIV-1 Suppression ex Vivo Tissue Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . Age &gt; /= 10 year &lt; /= 14 year age &lt; /= 18 year &lt; /= 21 year . 2 . Willing able communicate English . 3 . Willing able provide write informed consent assent take part study ( require , parent/guardian must provide consent ) . 4 . Willing able provide adequate information locator purpose . 5 . Understand agree local sexually transmit infection ( STI ) reporting requirement . 6 . HIVnegative positive document prior serologic test per report , willing undergo repeat HIV testing . 7 . Willing able take aspirin , aspirin contain medication , nonsteroidal antiinflammatory drug least 72 hour 72 hour flexible sigmoidoscopy . 8 . All female patient childbearing potential ( postmenarche ) must willing undergo urine pregnancy test screen . 9 . Must general good health , include normal renal function . 10 . Subjects &lt; 18 year old must schedule clinically indicate colonoscopy flexible sigmoidoscopy biopsy . 11 . HIVpositive participant ( Aim 1 ) : Must recent HIV polymerase chain reaction ( PCR ) document last 612 month verbal report Must tenofovir chronic cART regimen ( &gt; /= 1 month ) . Be reportedly compliant . CD4 T cell &gt; 250/cmm 1 . Known history inflammatory bowel disease . 2 . Abnormalities colorectal mucosa , significant colorectal symptom ( ) opinion clinician represent contraindication biopsy ( include limit presence unresolved injury , inflammatory condition local mucosa , presence symptomatic external hemorrhoid ) . 3 . Evidence know enteric infection time study visit . 4 . Participantreported symptom and/or clinical laboratory diagnosis active symptomatic rectal infection ( gonorrhea , Chlamydia , syphilis , clinically active perineal HSV ) . Note : Allow one rescreening document treatment ( 30 day ) case gonorrhea/chlamydia ( GC/CT ) identify screen . 5 . Pregnancy . 6 . Subjects poorly control medical condition ( e.g . diabetes , congestive heart failure ) . 7 . Chronic renal disease ( BUN serum creatinine &gt; 1.5 time upper normal limit ) . 8 . History presence impair gastrointestinal motility , history extensive small bowel resection ( great half length small intestine ) . 9 . Use warfarin heparin . 10 . Use systemic immunomodulatory medication within 4 week screen . 11 . Use investigational product within 4 week screen . 12 . Fever time endoscopy . Subjects reschedule later point fever resolve . 13 . Any clinical condition prior therapy , opinion investigator , would make patient unsuitable study unable comply study requirement . Such condition may include , limited , current recent history sever , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral disease .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>tenofovir</keyword>
	<keyword>miocrobicide</keyword>
	<keyword>endoscopy ( colonoscopy , sigmoidoscopy )</keyword>
	<keyword>adolescent</keyword>
	<keyword>pediatrics</keyword>
</DOC>